2,5-Morpholine Derivatives for HIV Protease Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV protease inhibitors are not suitable for all HIV-infected individuals due to adverse effects and rapid metabolism, leading to the need for new compounds that can effectively inhibit HIV protease and treat or prevent HIV infection and AIDS.
Innovation Solution
Development of 2,5-morpholine derivatives that inhibit HIV protease, preventing viral replication and used in the treatment, prophylaxis, and delay of AIDS progression, either alone or in combination with other anti-HIV agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HIV protease inhibitors are used to treat HIV infection, then HIV protease inhibition and viral load reduction are achieved, but adverse effects and rapid metabolism occur requiring frequent dosing
Solution Approach 1:
The patent modifies the chemical structure of protease inhibitors by introducing specific substituents (R1-R6 groups) at defined positions on the molecular scaffold. These structural parameter changes aim to alter the drug's metabolic stability and pharmacokinetic properties, reducing rapid clearance while maintaining protease inhibition effectiveness. The systematic variation of substituent groups allows optimization of the balance between efficacy and tolerability.
2Reliability
If current HIV protease inhibitors are administered frequently to maintain effective concentration, then viral replication is suppressed, but patient compliance and treatment simplicity deteriorate
Solution Approach 1:
The patent designs protease inhibitors with dynamic pharmacokinetic properties through strategic molecular modifications. The introduced substituent groups (R1-R6) are selected to optimize the drug's half-life and metabolic stability, enabling the inhibitor to maintain effective concentrations for extended periods. This dynamic optimization allows transition from frequent dosing to less frequent administration while preserving viral suppression.
3Reliability
If existing protease inhibitors are used to treat HIV, then initial treatment effectiveness is achieved, but resistance development occurs over time
Solution Approach 1:
The patent employs composite molecular structures combining multiple functional groups (R1-R6 substituents) on a core protease inhibitor scaffold. This composite design creates a more complex binding interaction with the viral protease, making it harder for the virus to develop resistance through simple point mutations. The multi-component molecular architecture provides multiple binding contacts that must all be disrupted for resistance to emerge.
4Reliability
If protease inhibitors are used to inhibit HIV protease, then viral protein processing is blocked, but metabolic clearance is rapid reducing drug availability
Solution Approach 1:
The patent systematically modifies pharmacokinetic parameters of protease inhibitors through controlled changes in molecular structure. Specific substituent groups (R1-R6) are introduced or modified to enhance metabolic stability by protecting against enzymatic degradation and reducing hepatic clearance. These parameter changes extend the drug's persistence in the bloodstream while preserving its ability to inhibit protease activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2,5-morpholine derivatives effectively inhibit HIV protease, offering an alternative for individuals who cannot tolerate existing therapies and reducing the risk of resistance, while also potentially delaying the progression of AIDS.
Implementation Method 1
The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV protease
Data Source
AI summary
The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.